Stockreport

Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle [Reuters]

Akero Therapeutics, Inc.  (AKRO) 
Last akero therapeutics, inc. earnings: 3/16 07:30 am Check Earnings Report
PDF a serious type of fatty liver disease formerly known as non-alcoholic steatohepatitis (NASH) as the race to tap a multi-billion dollar market intensifies. The approval [Read more]